Introduction: Several reports have demonstrated the surgical treatment strategy for patients with dialysis-associated spondylosis in the cervical spine (CDAS) with destructive spondyloarthropathy (DSA). However, studies focusing on the clinical outcome of patients with CDAS without DSA remain scarce. We aimed to review the treatment strategy of patients with CDAS but without DSA.
Methods: The clinical data and surgical records of consecutive patients with CDAS without DSA (n = 9; D-group) and cervical spondylotic myelopathy (CSM) (n = 30; C-group) who underwent modified double-door laminoplasty(DDL) were reviewed retrospectively. We investigated four radiologic factors in the pre-and postoperative periods that have been reported to be the risk factors for worsening of clinical symptoms in various studies and examined statistical comparison between the D and C groups.
Results: In the D group, the pre- versus postoperative C2-C7 sagittal angles were not significantly different, and only two patients (22%) had kyphosis postoperatively. There was a significant difference in the pre- and postoperative C2-C7 angles in the two groups (P = 0.031). Regarding the change in segmental alignment, the local open angle increased at the C4/C5 level in the D group. Also there was a significant difference in the local angles between the two groups at C4/5 and C5/6 (P = 0.00038, and 0.037), suggesting that postoperative segmental mobility at C4/5 and C5/6 was higher in the D group than in the C group.
Conclusions: In the present study, DDL in patients with CDAS without DSA did not adversely affect the postoperative alignment and stability compared with CSM patients with CSM. However, patients in the D group may have a chance to develop DSA change at the C4/5 level in the future, and careful long-term follow-up is warranted.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698522 | PMC |
| http://dx.doi.org/10.22603/ssrr.2017-0068 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Real world experience with cladribine tablets for multiple sclerosis at four academic multiple sclerosis centers.
Mult Scler Relat Disord
January 2025
John L Trotter Multiple Sclerosis Center, Washington University, St. Louis, Missouri, USA.
Background: Cladribine tablets (CladT) are a multiple sclerosis (MS) disease-modifying therapy (DMT) with safety and efficacy established in the CLARITY trial and extension. A better understanding of the role of CladT in real-world populations is needed, including the clinical and radiographic trajectories of persons with MS (PwMS) treated with CladT and how CladT compares to other MS DMTs.
Methods: PwMS receiving CladT at 4 tertiary MS centers were identified and characterized.
Identifying Cladribine prescription pattern in MS: an Italian multicentre study.
Ther Adv Neurol Disord
January 2025
Department of Medical and Surgical Sciences, University of Foggia, Foggia 71122, Italy.
Background: Characterizing Cladribine tablets prescription pattern in daily clinical practice is crucial for optimizing multiple sclerosis (MS) treatment.
Objectives: To describe efficacy, safety profile and new disease-modifying therapy (DMT) prescriptions following Cladribine treatment.
Design: Independent retrospective cohort study in patients followed at six Italian MS centres.
Evaluation of the Toxicity and Outcomes of the Combination of Midostaurin and CLAG-M in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML): A Multicenter Retrospective Analysis.
Ann Pharmacother
January 2025
Department of Hematologic Malignancies, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Background: Addition of midostaurin to standard "7+3" (cytarabine and anthracycline) significantly prolongs overall and event-free survival. At University of Washington/Fred Hutchinson Cancer Center (UW/FHCC), the standard regimen for newly diagnosed (ND) and relapsed/refractory (R/R) AML is cladribine, high-dose cytarabine, GCSF, and mitoxantrone (CLAG-M); midostaurin is added if FLT3-mutated. There is limited data on the use of FLT3-inhibitors with high-dose cytarabine regimens in AML.
View Article and Find Full Text PDFEffects of the shortened dental arch on oral function in older adults: A prospective cohort study.
Heliyon
December 2024
Department of Geriatric Dentistry, Osaka Dental University, Osaka, Japan.
Statement Of The Problem: Previous longitudinal studies have found that patients with shortened dental arches (SDA) have a higher risk of long-term tooth loss than complete dental arch (CDA). However, the difference between SDA and CDA concerning oral function has yet to be demonstrated.
Purpose: We aimed to clarify the influence of molar occlusal support on oral function in SDA and CDA participants cross-sectionally and longitudinally.
New strategies to manage the safety of cladribine in patients with multiple sclerosis.
Expert Opin Drug Saf
January 2025
Department of Medical and Surgical Sciences and Advanced Technologies "G.F. Ingrassia", University of Catania, Catania, Italy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!